Effects of ONO-2506PO in Patients With Alzheimer's Disease

Ono Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Alzheimer's Disease

Treatments: Drug: ONO-2506PO

Study type: Interventional

Funder types: Industry

Identifiers

NCT00083421

ONO-2506POU010

Details and patient eligibility

About

The purpose of this study is to establish the presence of an effect of treatment with ONO-2506PO in patients with Alzheimer's Disease, based upon cognitive and global scales.

Enrollment: 647 patients

Sex: All

Ages: 50 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of probable Alzheimer's Disease using NINCDS/ADRDA criteria
• Standardized MMSE Score of 13 to 24 points (inclusive)
• Modified Hachinski score equal or less than 4

Exclusion criteria

• Serious systemic disease that may preclude survival to study completion
• Other illnesses that may include dementive features

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind